FL
57 programs · 55 companies
Programs
57
Companies
55
Trials
46
MOAs
35
KRASG12DiBiTEBCL-2iCD3xCD20CDK2iAuroraAiSTINGagJAK1iGLP-1agBTKi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexarelsin | Phase 1 | DLL3 | ||
| DSN-7360 | Approved | SGLT2 | ||
| Rimaosocimab | Preclinical | FXIa | ||
| ITC-1028 | Phase 2 | BCMA | ||
| Cevimavacamten | NDA/BLA | Menin | ||
| Pemitinib | Preclinical | BTK | ||
| CSL-8235 | Phase 1/2 | IL-17A | ||
| RDY-9256 | Phase 1/2 | TYK2 | ||
| Datozasiran | NDA/BLA | RET | ||
| Gelibrutinib | Phase 1 | PCSK9 | ||
| Talavorutinib | NDA/BLA | Cl18.2 | ||
| Zenocagene | Approved | IL-23 | ||
| Miritapinarof | Phase 2 | IL-17A | ||
| GUS-IIT-176 | Phase 2/3 | TROP-2 | ||
| IPS-9466 | NDA/BLA | TROP-2 | ||
| IMV-6752 | Phase 2 | CDK2 | ||
| IMV-6044 | Phase 1/2 | BCMA | ||
| ATL-9462 | Phase 2/3 | CD38 | ||
| RAP-6712 | NDA/BLA | PD-L1 | ||
| Tezezanubrutinib | Preclinical | SHP2 | ||
| Teracilimab | Phase 2/3 | TIGIT | ||
| CTM-2131 | Phase 3 | IL-17A | ||
| Adagralemzoparlimab | Phase 2/3 | PD-L1 | ||
| Talabrutinib | Phase 1/2 | GPRC5D | ||
| SWT-3857 | Phase 1 | CDK4/6 | ||
| Bemacapivasertib | Phase 2 | IL-23 | ||
| KNS-8287 | Phase 2 | Nectin-4 | ||
| Dararapivir | Phase 2/3 | JAK2 | ||
| PRO-1192 | Phase 1 | GIP-R | ||
| Mavubrutinib | Phase 3 | GLP-1R | ||
| LAE-3866 | Phase 1/2 | FXIa | ||
| Daraglumide | Preclinical | PD-1 | ||
| CAR-3300 | Approved | FXIa | ||
| Talarasimod | Phase 1/2 | AuroraA | ||
| PRT-8732 | Phase 2/3 | PLK4 | ||
| ACL-6459 | Phase 3 | FGFR | ||
| TUR-4491 | NDA/BLA | C5 | ||
| Suratapinarof | NDA/BLA | PD-L1 | ||
| NOI-8348 | Preclinical | Menin | ||
| GLA-2545 | Phase 2 | WEE1 | ||
| Motaratamab | Phase 2/3 | MDM2 | ||
| IMV-3466 | Phase 1 | CD38 | ||
| VEC-6874 | Phase 2/3 | Tau | ||
| DBV-5518 | Phase 1 | USP1 | ||
| ACE-3611 | NDA/BLA | CDK4/6 | ||
| PAC-8776 | Preclinical | TYK2 | ||
| Teraosocimab | Phase 1 | EZH2 | ||
| Bematinib | Phase 2 | KRASG12C | ||
| Nidaglumide | Approved | C5 | ||
| Teratenlimab | Preclinical | TYK2 | ||
| Mavuderotide | Approved | CD47 | ||
| SIA-1629 | Phase 2/3 | KIF18A | ||
| TEV-7734 | Approved | KRASG12C | ||
| RIK-IIT-658 | Phase 3 | C5 | ||
| Motanesiran | Phase 2/3 | MDM2 | ||
| FRO-509 | Approved | KIF18A | ||
| Olpabrutinib | Phase 1/2 | KIF18A |
Trials (46)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05618377 | Pexarelsin | Phase 1 | Not yet recr... |
| NCT04703881 | Pexarelsin | Phase 1 | Terminated |
| NCT05944607 | DSN-7360 | Approved | Completed |
| NCT07127710 | DSN-7360 | Approved | Terminated |
| NCT07591826 | Cevimavacamten | NDA/BLA | Not yet recr... |
| NCT03474716 | Pemitinib | Preclinical | Terminated |
| NCT03655756 | CSL-8235 | Phase 1/2 | Terminated |
| NCT08478360 | CSL-8235 | Phase 1/2 | Not yet recr... |
| NCT03953622 | RDY-9256 | Phase 1/2 | Active |
| NCT03068749 | Gelibrutinib | Phase 1 | Completed |
| NCT05804000 | Talavorutinib | NDA/BLA | Recruiting |
| NCT08592486 | Talavorutinib | NDA/BLA | Completed |
| NCT03520771 | Zenocagene | Approved | Active |
| NCT06568751 | GUS-IIT-176 | Phase 2/3 | Not yet recr... |
| NCT03644811 | IPS-9466 | NDA/BLA | Terminated |
| NCT06426859 | IMV-6752 | Phase 2 | Active |
| NCT08232161 | RAP-6712 | NDA/BLA | Not yet recr... |
| NCT08033126 | Tezezanubrutinib | Preclinical | Recruiting |
| NCT03999075 | CTM-2131 | Phase 3 | Completed |
| NCT03383515 | CTM-2131 | Phase 3 | Not yet recr... |